Physician profile
William Erwin
NPI 1538154158
$1,124.67
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $104 · 2021: $355.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $355.41 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $300.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.77 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $56.13 | 2019-2020 | |
| Philips North America LLC | $49.48 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $46.72 | 2020 | |
| Glaxosmithkline, LLC. | $38.60 | 2019 | |
| Grifols USA, LLC | $21.71 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.27 | 2019 | |
| Genentech USA, INC. | $17.45 | 2019 | |
| Merck Sharp & Dohme LLC | $15.83 | 2019 | |
| Genzyme Corporation | $14.07 | 2019 | |
| Pfizer INC. | $12.54 | 2019 | |
| Gilead Sciences, INC. | $12.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Erwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.